KHL Foundation Reports the Likely First Human Partial Epigenetic Reprogramming Treatments
Key claim: KHL Foundation reports that entrepreneurial longevity-community individuals received the likely first human partial epigenetic reprogramming treatments via AAV gene therapy through medical-tourism providers, ahead of Life Biosciences’ formal optic-neuropathy trial.
Abstract
The first human application of partial epigenetic reprogramming of aged tissues, using adeno-associated viral (AAV) vectors, was not in fact the first patient dosed in the recently launched Life Biosciences clinical trial for optic neuropathy. Instead, a few older and entrepreneurial individuals in the longevity community made use of the AAV gene therapy experience accumulated in recent years by organizations in the more reputable end of the medical tourism industry (e.g. Triple Helix Science in particular, but also BioViva and others with lower profiles) in order to responsibly manufacture and use reprogramming therapy. The medical tourism community tends not to generate formally published and peer-reviewed data, sadly, but in this case some of those involved may choose to share data further along the line, given […]
Why this matters
If the KHL Foundation account holds up, partial epigenetic reprogramming has crossed into humans not through a regulated trial but through medical-tourism gene therapy — a first-in-human milestone with zero peer-reviewed safety data and permanent AAV exposure. The divergence between the trend (patients already dosed) and the evidence (animal models plus one not-yet-reported optic-neuropathy trial) is itself the story for this area’s consumer-protection surface.